Arbutus Biopharma (ABUS) Financials: History & Chart

Arbutus Biopharma Corp(ABUS)

Biotechnology · Warminster, PA

$4.45-0.22 (-4.82%)

Delayed quote: Oct 6, 2026, 2:00 PM EDT

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Warminster, PA

19 employees

www.arbutusbio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Lindsay Androski

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	181.72M	1.01M	179.13M	1.05M	529K	10.74M	1.76M	1.57M	1.34M
Cost of Goods Sold	33K	0.00	11K	11K	11K	0.00	8.96M	8.81M	0.00
Gross Profit	181.69M	1.01M	179.12M	1.04M	518K	10.74M	-7.20M	-7.24M	1.34M
Gross Profit Margin	100.0%	100.0%	100.0%	99.0%	97.9%	100.0%	-407.9%	-459.7%	100.0%
Total Operating Expenses	34.47M	6.98M	10.00M	8.68M	8.81M	9.25M	27.46M	6.70M	22.78M
Research & Development	17.80M	2.90M	4.12M	5.01M	5.78M	5.50M	8.96M	8.81M	14.27M
Selling, General & Administrative	16.48M	3.87M	5.88M	3.70M	3.03M	3.33M	5.83M	8.43M	4.54M
Operating Income (EBIT)	147.22M	-5.96M	169.12M	-7.64M	-8.29M	1.49M	-34.66M	-13.93M	-21.44M
Operating Margin	81.0%	-588.2%	94.4%	-727.3%	-1567.7%	13.9%	-1964.7%	-885.2%	-1601.2%
Income Before Tax (EBT)	153.05M	-5.14M	169.69M	-3.76M	-7.74M	2.52M	-24.53M	-12.53M	-19.72M
Interest Income	3.49M	842K	815K	877K	952K	1.04M	1.20M	1.46M	1.75M
Interest Expense	76K	18K	17K	18K	23K	28K	28K	30K	29K
Other Income/Expense	5.84M	821K	578K	3.89M	551K	1.03M	10.13M	1.40M	1.72M
Net Income	153.05M	-5.14M	169.69M	-3.76M	-7.74M	2.52M	-24.53M	-12.53M	-19.72M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	84.2%	-507.2%	94.7%	-357.4%	-1463.5%	23.5%	-1390.4%	-796.2%	-1472.5%
EBITDA	147.26M	-5.95M	169.13M	-7.63M	-8.28M	1.50M	-34.33M	-13.60M	-21.10M
EBITDA Margin	81.0%	-587.1%	94.4%	-726.3%	-1565.6%	14.0%	-1945.9%	-864.0%	-1576.1%
Depreciation & Amortization	44K	11K	11K	11K	11K	11K	333K	333K	336K
EPS Basic	0.79	-0.03	0.88	-0.02	-0.04	0.01	-0.13	-0.07	-0.10
EPS Diluted	0.78	-0.03	0.87	-0.02	-0.04	0.01	-0.13	-0.07	-0.10
Weighted Average Basic Shares	197.47M	197.47M	193.77M	191.60M	191.78M	191.55M	190.71M	185.61M	189.00M
Weighted Average Diluted Shares	197.47M	197.47M	195.21M	191.60M	191.78M	192.40M	190.71M	189.96M	189.00M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	14.08M	6.17M	18.14M	39.02M	10.99M	6.91M	6.01M	5.90M
Cost of Goods Sold	363K	0.00	0.00	0.00	0.00	47.48M	57.60M	57.90M
Gross Profit	13.72M	6.17M	18.14M	39.02M	10.99M	-40.57M	-51.59M	-52.00M
Gross Profit Margin	97.4%	100.0%	100.0%	100.0%	100.0%	-586.7%	-858.3%	-881.4%
Total Operating Expenses	40.77M	82.49M	96.24M	104.47M	84.51M	17.24M	92.31M	76.10M
Research & Development	25.24M	54.04M	73.70M	84.41M	65.50M	49.34M	57.60M	57.90M
Selling, General & Administrative	15.89M	22.11M	22.48M	17.83M	17.14M	14.85M	17.73M	16.00M
Operating Income (EBIT)	-27.05M	-76.32M	-78.10M	-65.46M	-73.52M	-57.81M	-143.90M	-89.80M
Operating Margin	-192.1%	-1236.7%	-430.5%	-167.8%	-669.1%	-836.1%	-2394.0%	-1522.0%
Income Before Tax (EBT)	-33.50M	-69.92M	-72.85M	-65.01M	-76.25M	-63.74M	-166.38M	-61.40M
Interest Income	4.07M	6.58M	5.69M	2.19M	127K	741K	2.11M	3.00M
Interest Expense	97K	137K	459K	1.73M	2.86M	4.01M	2.11M	200K
Other Income/Expense	-6.45M	6.40M	5.25M	444K	-2.73M	-5.94M	-22.48M	28.44M
Net Income	-33.50M	-69.92M	-72.85M	-69.46M	-76.25M	-63.74M	-153.72M	-57.10M
Income Tax Expense	0.00	0.00	0.00	4.44M	0.00	0.00	-12.66M	-4.30M
Net Profit Margin	-237.9%	-1133.0%	-401.6%	-178.0%	-693.9%	-922.0%	-2557.4%	-967.8%
EBITDA	-26.69M	-74.94M	-76.70M	-64.03M	-71.77M	-55.83M	-141.87M	-87.62M
EBITDA Margin	-189.5%	-1214.4%	-422.8%	-164.1%	-653.2%	-807.5%	-2360.2%	-1485.1%
Depreciation & Amortization	363K	1.38M	1.40M	1.43M	1.75M	1.98M	2.03M	2.18M
EPS Basic	-0.17	-0.38	-0.44	-0.46	-0.73	-0.86	-2.69	-1.03
EPS Diluted	-0.17	-0.38	-0.44	-0.46	-0.73	-0.86	-2.69	-1.03
Weighted Average Basic Shares	191.60M	185.61M	165.96M	150.94M	106.24M	75.84M	57.09M	55.30M
Weighted Average Diluted Shares	191.60M	185.61M	165.96M	150.94M	106.24M	75.84M	57.09M	55.30M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.